Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2017

View Archived Issues

Rich Pharmaceuticals signs agreement to support HypGen's development of Parkinson's treatments

Mallinckrodt completes license transfer of Synacthen Depot to West Pharmaceuticals

Managed access program launched for eteplirsen to treat DMD amenable to exon 51 skipping

Sacituzumab govitecan demonstrates an effective therapeutic profile in patients with mSCLC

Johnson & Johnson offers overview of second quarter 2017

LabCorp makes ADAMTS13 test available in U.S.

Grant to support OSE's development of new immune checkpoint inhibitor OSE-172

MEDI-1814 suppresses Abeta42 levels in animal studies

Ablynx collaborates with Sanofi on Nanobody therapeutics for immune-mediated inflammatory diseases

Celyad initiates phase I study of CYAD-01 in metastatic colorectal cancer

Phase III safety results on revefenacin for COPD to support NDA submission

BACE1 inhibitor JNJ-54861911 suppresses beta-amyloid in animal models

Bayer Pharma patents IRAK-4 inhibitors

Mission Therapeutics divulges deubiquitylating enzyme inhibitors

Gruenenthal discloses PDE4B inhibitors

Immune Pharmaceuticals continues plan to spin off Cytovia

Chiesi Farmaceutici presents MAPK inhibitors

IMG-7289 advances into phase IIa portion of trial in AML and MDS

Rolling NDA submission completed for CAM-2038 to treat opioid use disorder

FDA accepts for review Hizentra sBLA for chronic inflammatory demyelinating polyneuropathy

Marina Biotech enters license agreement for use of SMARTICLES to deliver antisense DNA therapeutics

Aerie reports 12-month safety data from Roclatan registration trial

European approval for Kyntheum for moderate to severe plaque psoriasis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...